ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
63,765.04
0.56%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Passage Bio Inc (PASG) Quote

Passage Bio Inc

Passage Bio Inc (PASG)

NASDAQ
1.32
0.10
(8.20%)
Closed April 28 4:00PM
Delayed by 15 minutes
1.27
-0.05
(-3.79%)
After Hours: 6:37PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.27
Bid
1.25
Ask
1.32
Volume
75,861
1.22 Day's Range 1.33
0.5751 52 Week Range 1.79
Market Cap
72.278M
Previous Close
1.22
Open
1.22
Last Trade
50
@
1.32
Last Trade Time
Financial Volume
$ 96,243
VWAP
1.2687
Average Volume (3m)
364,492
Shares Outstanding
55,598,796
Dividend Yield
-
PE Ratio
-0.71
Earnings Per Share (EPS)
-1.84
Revenue
-
Net Profit
-102.06M

About Passage Bio Inc

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.passagebio.com/home/default.aspx
Headquarters
Wilmington, Delaware, USA
Founded
1970
Passage Bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PASG. The last closing price for Passage Bio was $1.22. Over the last year, Passage Bio shares have traded in a share price range of $ 0.5751 to $ 1.79.

Passage Bio currently has 55,598,796 shares outstanding. The market capitalization of Passage Bio is $72.28 million. Passage Bio has a price to earnings ratio (PE ratio) of -0.71.

PASG Latest News

More News

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

April 22 2024
GlobeNewswire Inc.

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship application deadline is April 26 for the...

March 05 2024
GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans

March 04 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

March 04 2024
Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 04 2024
Edgar (US Regulatory)

Form 8-K - Current report

March 04 2024
Edgar (US Regulatory)

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical trial site expansion into Europe and...

March 04 2024
GlobeNewswire Inc.

Form 8-K - Current report

February 29 2024
Edgar (US Regulatory)

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

February 27 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 14 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.075.833333333331.21.331.1006937111.16598339CS
4-0.09-6.617647058821.361.451.10061321101.29667887CS
120.330.92783505150.971.790.93813644921.39032421CS
260.689.5522388060.671.790.57515008141.00836436CS
520.2828.28282828280.991.790.57513533870.96520529CS
156-15.67-92.502951593916.9419.840.57513316254.0548068CS
260-21-94.297260889122.2738.230.57513162088.09355597CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

PASG Discussion

View Posts
Sirpeter Sirpeter 1 month ago
Running... boom!!!
👍️0
Monksdream Monksdream 1 month ago
PASG under $2
👍️0
glenn1919 glenn1919 1 month ago
PASG..........................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
PASG new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
PASG setting up nicely. Another beautiful call by the only true chartist around
👍️0
Sirpeter Sirpeter 2 months ago
Yup yup yup...
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
PASG...NEXT CRDL
👍️0
glenn1919 glenn1919 2 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
PASG under $2
👍️0
turning stone turning stone 3 months ago
As a new investor in PASG, I am looking forward to another high roller in the next number of years. I bought ARNA years ago at 1.90 and rode it out to $99/share when they were bought out by Phizer Pharm. I would like to have my 5 grandkids share the spoils on this one. With a multi-pipe line, a couple should make it to the end of the line with FDA approval. At the number of shares I purchased multiple times I can afford to run for the hills if a sudden disaster should hit this one. This company is 21 miles from my home and I will stop by shortly and have a sit down with their home-based PR. person. Good luck to all. You may also want to look at BLRX {BIO-Line Inc }










👍️0
Walter4 Walter4 4 months ago
Data readout should be incoming shortly
👍️ 1
Monksdream Monksdream 8 months ago
PASG new 52 week low
👍️0
catinhat catinhat 2 years ago
So...anybody out there? Thoughts on upcoming abstract, etc?

Recent long.
👍️0
dealerschool2006 dealerschool2006 3 years ago
PASG down from panic selling due to the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $22.00 per share.
👍️0

Your Recent History

NASDAQ
PASG
Passage Bio
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved